Publications by authors named "Ad Roffel"

Claim this Profile
C
Contraception Requirements in Early Clinical Trials: Considerations Towards an Evidence-Based Approach.
Tatyana Dubich, Ad F Roffel

Pharmaceut Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Stefanie Reif, Marcus-Hillert Schultze-Mosgau, Anna Engelen, Isabel Piel, Karsten Denner, Ad Roffel

Eur J Drug Metab Pharmacokinet· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
.
.
Jiyuan Ma, Oscar L Laskin, Ad F Roffel, Wouter H J Vaes, Bowen Tang

Drug Metab Dispos· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans.
John Dodd, Robert Jordan, Marie Makhlina, Keith Barnett, Ad Roffel

Front Immunol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?
Tal Burt, Ad F Roffel, Oliver Langer, Kirsten Anderson, Joseph DiMasi

Clin Transl Sci· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictability of Elimination and Excretion of Small Molecules in Animals and Humans, and its Impact on Dosimetry for human ADME Studies with Radiolabeled Drugs.
Ad Roffel, Jan Jaap van Lier, Gerk Rozema, Ewoud-Jan van Hoogdalem

Curr Rev Clin Exp Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data.
Alexander D James, Hilmar Schiller, Cyrille Marvalin, Yi Jin, Hubert Borell, Ad F Roffel

Pharmacol Res Perspect· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human ADME for YH12852 using wavelength scanning cavity ring-down spectroscopy (WS-CRDS) after a low radioactivity dose.
Anhye Kim, Stephen R Dueker, Feng Dong, Ad F Roffel, Sang-Won Lee

Bioanalysis· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers.
Gabriel M Fox, Ad F Roffel, Jan Hartstra, Linda A Bussian, Sjoerd P van Marle

Clin Pharmacol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [ C]Seletalisib (UCB5857) in Healthy Subjects.
Eric Helmer, Jean-Marie Nicolas, Jeff Long, Ad F Roffel, Emma Jones

J Clin Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species.
Lene Jensen, Hans Helleberg, Ad Roffel, Jan Jaap van Lier, Inga Bjørnsdottir

Eur J Pharm Sci· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunities in low-level radiocarbon microtracing: applications and new technology.
Le Thuy Vuong, Qi Song, Hee Joo Lee, Ad F Roffel, Seok-Ho Shin

Future Sci OA· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis